Profile data is unavailable for this security.
About the company
Adocia SA is a clinical-stage biotechnology company based in France. The Company specializes in the development of formulations of already-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary technological platform BioChaperone is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. The Company’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two formulations of insulin analog lispro (BioChaperone Lispro U100 and U200), a combination of basal insulin glargine and insulin lispro (BioChaperone Combo), and a combination of prandial insulin with amylin analog pramlintide: M1Pram. Its preclinical pipeline includes three products BioChaperone LisPram, BioChaperone Glargine GLP-1 and BioChaperone Glucagon GLP1.
- Revenue in EUR (TTM)5.73m
- Net income in EUR-20.55m
- Incorporated2006
- Employees100.00
- LocationAdocia SA115 avenue LacassagneLYON 69003FranceFRA
- Phone+33 472610610
- Fax+33 472363967
- Websitehttps://www.adocia.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Valbiotis SA | 4.39m | -9.14m | 64.92m | 48.00 | -- | 4.37 | -- | 14.78 | -0.8427 | -0.8427 | 0.3832 | 0.9411 | 0.1816 | 0.7079 | 1.76 | 91,479.16 | -37.81 | -36.56 | -55.22 | -50.24 | 88.93 | 49.62 | -208.22 | -812.27 | 2.79 | -39.11 | 0.3656 | -- | 163.42 | 204.47 | -41.83 | -- | -14.52 | -- |
AFYREN SA | 3.38m | -9.59m | 70.78m | 122.00 | -- | 1.15 | -- | 20.95 | -0.3696 | -0.3696 | 0.1303 | 2.37 | 0.0435 | -- | 5.39 | 27,696.72 | -12.35 | -9.58 | -13.42 | -10.46 | 92.63 | 95.57 | -283.69 | -162.61 | -- | -1.62 | 0.0719 | -- | -2.23 | -- | -4.20 | -- | -- | -- |
AB Science SA | 777.00k | -16.89m | 99.87m | 89.00 | -- | -- | -- | 128.54 | -0.3561 | -0.3561 | 0.0164 | -0.3879 | 0.0284 | 0.394 | 2.50 | 7,471.15 | -61.64 | -70.81 | -237.22 | -316.63 | 88.16 | 91.37 | -2,173.10 | -1,225.49 | 1.41 | -- | 135.44 | -- | -40.39 | -11.24 | 5.86 | -- | 5.07 | -- |
Maat Pharma SA | 2.23m | -19.72m | 108.03m | 50.00 | -- | 5.28 | -- | 48.49 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
Eurofins-Cerep SA | 46.17m | 9.21m | 109.96m | 233.00 | 11.94 | 1.83 | 9.82 | 2.38 | 1,826.41 | 1,826.41 | 9,160.00 | 11,939.29 | 0.6814 | 1.66 | 6.04 | 220,892.00 | 13.60 | 15.19 | 16.06 | 18.94 | 85.57 | 67.30 | 19.95 | 19.72 | 5.17 | 112.42 | 0.00005 | 0.00 | 14.45 | 14.30 | 17.09 | 24.52 | -- | -- |
DBV Technologies SA | 4.90m | -94.65m | 120.08m | 88.00 | -- | 0.78 | -- | 24.48 | -1.00 | -1.00 | 0.052 | 1.60 | 0.0209 | -- | 0.3738 | 71,076.30 | -40.35 | -64.67 | -46.22 | -80.94 | -- | 91.59 | -1,929.97 | -1,345.10 | -- | -- | 0.0128 | -- | -15.14 | -18.45 | 2.08 | -- | -38.41 | -- |
Adocia SA | 5.73m | -20.55m | 120.37m | 100.00 | -- | -- | -- | 21.03 | -2.36 | -2.36 | 0.6532 | -1.90 | 0.1823 | -- | 16.79 | 55,048.08 | -65.43 | -25.65 | -341.43 | -37.22 | -- | -- | -358.85 | -101.11 | 0.5924 | -2.78 | 2.81 | -- | 692.73 | -10.08 | 69.67 | -- | -40.08 | -- |
Ose Immunotherapeutics SA | 2.23m | -23.00m | 122.77m | 62.00 | -- | 5.30 | -- | 55.13 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
Transgene SA | 7.63m | -22.33m | 125.06m | 158.00 | -- | 7.99 | -- | 16.38 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
Eurobio Scientific SA | 130.00m | 4.84m | 148.33m | 137.00 | 33.38 | 0.8987 | 6.37 | 1.14 | 0.4315 | 0.4315 | 11.59 | 16.02 | 0.4018 | 3.19 | 4.31 | 948,927.00 | 1.49 | 16.91 | 1.80 | 21.53 | 47.11 | 50.95 | 3.72 | 23.34 | 2.32 | 2.81 | 0.3666 | 0.00 | -14.81 | 20.80 | -80.61 | -- | 20.02 | -- |
Inventiva SA | 17.48m | -110.43m | 155.33m | 112.00 | -- | -- | -- | 8.89 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
Genfit SA | 38.18m | -28.89m | 159.62m | 159.00 | -- | 2.35 | -- | 4.18 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
Aelis Farma SA | 9.05m | -5.08m | 173.22m | 26.00 | -- | 13.06 | -- | 19.13 | -0.3907 | -0.3907 | 0.7019 | 0.9957 | 0.2765 | -- | 2.41 | 348,230.80 | -15.51 | -24.53 | -25.59 | -40.55 | -- | -- | -56.09 | -109.62 | 2.47 | -- | 0.1547 | -- | 137.70 | -- | 64.46 | -- | 37.35 | -- |
Cellectis SA | 8.58m | -102.20m | 174.88m | 235.00 | -- | 2.20 | -- | 20.37 | -1.75 | -1.64 | 0.1553 | 1.10 | 0.0309 | -- | 13.71 | 36,529.07 | -39.24 | -24.08 | -60.81 | -30.69 | -- | -64.64 | -1,270.92 | -308.24 | -- | -5.08 | 0.5429 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
Innate Pharma SA | 51.90m | -7.57m | 178.30m | 179.00 | -- | 3.43 | -- | 3.44 | -0.0939 | -0.0939 | 0.6451 | 0.642 | 0.2648 | -- | 5.67 | 289,949.70 | -3.86 | -8.83 | -4.87 | -12.11 | 94.50 | 93.17 | -14.59 | -55.55 | -- | -- | 0.6408 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
Holder | Shares | % Held |
---|---|---|
Uzes Gestion SAas of 28 Mar 2024 | 30.00k | 0.21% |
CGM � Azimut Monaco SAas of 29 Feb 2024 | 11.00k | 0.08% |
Gestys SAas of 26 Jan 2024 | 1.10k | 0.01% |
Iris Finance SAas of 31 Dec 2018 | 0.00 | 0.00% |